EMEA-000311-PIP06-18
Key facts
Invented name |
Stelara
|
Active substance |
Ustekinumab
|
Therapeutic area |
Immunology-Rheumatology-Transplantation
|
Decision number |
P/0178/2019
|
PIP number |
EMEA-000311-PIP06-18
|
Pharmaceutical form(s) |
|
Condition(s) / indication(s) |
Treatment of Systemic Lupus Erythematosus (SLE)
|
Route(s) of administration |
|
Contact for public enquiries |
Janssen Cilag International NV
Tel. +3214602111 |
Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|